Biotechnology Late Friday, Janssen announced that the US Food and Drug Administration has granted accelerated approval for Darzalex Faspro (the subcutaneous formulation of daratumumab), in combination with bortezomib, cyclophosphamide and dexamethasone (VCd or CyBorD for short), for the treatment of newly-diagnosed light chain (AL) amyloidosis. 16 January 2021